Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The pharmaceuticals market in Cyprus has been experiencing steady growth in recent years.
Customer preferences: Customers in Cyprus have been showing a growing preference for generic drugs, which are more affordable than their branded counterparts. This trend is in line with the global shift towards generic drugs, as customers become more cost-conscious. Additionally, there has been an increased demand for over-the-counter (OTC) drugs, as customers seek to self-medicate for minor ailments.
Trends in the market: One of the key trends in the pharmaceuticals market in Cyprus is the increasing focus on research and development. Major pharmaceutical companies are investing heavily in R&D to develop new drugs and treatments. This trend is driven by the need to address unmet medical needs, as well as the potential for significant profits from successful new drugs. Another trend in the market is the increasing adoption of digital technologies, such as telemedicine and e-prescriptions. These technologies are improving access to healthcare services and making it easier for customers to obtain the medications they need.
Local special circumstances: Cyprus has a small population, which means that the pharmaceuticals market is relatively small compared to other countries. However, the country has a well-developed healthcare system and a high level of healthcare spending per capita. Additionally, the country's location at the crossroads of Europe, Asia, and Africa makes it an attractive market for pharmaceutical companies looking to expand their reach.
Underlying macroeconomic factors: One of the key macroeconomic factors driving the pharmaceuticals market in Cyprus is the country's aging population. As the population ages, there is an increased demand for healthcare services and medications to treat age-related illnesses. Additionally, the country's high level of healthcare spending is supported by its strong economy and high GDP per capita. Finally, Cyprus is a member of the European Union, which means that it is subject to EU regulations and standards for pharmaceuticals. This has helped to ensure the safety and quality of medications sold in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)